Enanta Pharmaceuticals | ENTA - Los Gastos De Explotación

Precio De Mercado
14.20
Cambio Diario
-1.21 -7.85%
Mensual
5.11%
Anual
97.77%
Q1 Expectativa
13.86




Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.81B 13.45B 2025-12
Amgen USD 5.9B 773M 2025-12
Anika Therapeutics USD 146.8M 867K 2025-09
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Biogen USD 1.88B 81.4M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 38.47M 4M 2024-09
Immunic USD 25.73M 2.91M 2024-09
Incyte USD 1.12B 3.53B 2025-12
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
J&J USD 18.97B 2.38B 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 10.16B 558M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.86B 115M 2025-09
Novavax USD 218.53M 34.86M 2024-09
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12